Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2023 | ST2 and REG3α as predictive biomarkers for GvHD

James Ferrara • 24 Apr 2023
EBMT 2023
General

James Ferrara, MD, DSc, Icahn School of Medicine at Mount Sinai, New York City, NY, outlines currently used biomarkers for graft-versus-host disease (GvHD), commenting on systemic inflammation biomarkers TNFR1 and TIM-3, and biomarkers for gastrointestinal (GI) tissue damage ST2 and REG3α. This interview was recorded at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

US patent for serum biomarkers of GVHD

More from James Ferrara

2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
1:54
A novel clinical trial endpoint for acute GvHD
James Ferrara • 24 Apr 2023
0:42
Vedolizumab for GI acute GvHD prophylaxis after allogeneic transplantation
James Ferrara • 24 Apr 2023
3:25
Inhibition of RIP1 to prevent acute GvHD
James Ferrara et al. • 23 Feb 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals